InMed Pharmaceuticals
Yahoo Finance • 2 years ago
Presenting on the Emerging Growth Conference on March 8 Register Now
MIAMI, March 07, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 51st Emerging Growth Conference on March 8, 2023. The Emerging Growth Conference identifies companie... Full story
Yahoo Finance • 2 years ago
InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update
Closed calendar year 2022 with strong cash position of $11.5 millionApproaches completion of enrollment for Ph 2 clinical trial in EBAdvances research using rare cannabinoids in treating glaucoma and neurodegenerative diseases such as Alzh... Full story
Yahoo Finance • 2 years ago
InMed Provides Business Update and Milestones for 2023
Complete Phase 2 clinical trial enrollment in Epidermolysis Bullosa in 1Q 2023Progress preclinical research in glaucoma in preparation for human trialsAdvance research using rare cannabinoids in treating neurodegenerative diseases such as... Full story
Yahoo Finance • 2 years ago
InMed Announces Results of 2022 Annual General Meeting
VANCOUVER, British Columbia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabino... Full story
Yahoo Finance • 2 years ago
InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market
VANCOUVER, British Columbia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabino... Full story
Yahoo Finance • 2 years ago
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
VANCOUVER, British Columbia, Nov. 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabino... Full story
Yahoo Finance • 2 years ago
InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada ("NSERC") Alliance Grant Funding
Targeting neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’sIdentified two lead cannabinoid analog compounds for in vivo studiesNSERC grant funding supports InMed’s collaborative research projects with Dr. Kumar f... Full story
Yahoo Finance • 2 years ago
InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update
VANCOUVER, British Columbia, Nov. 11, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabino... Full story
Yahoo Finance • 2 years ago
InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business
VANCOUVER, British Columbia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare cannabinoids and cannabinoid analogs, to... Full story
Yahoo Finance • 2 years ago
InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria
VANCOUVER, British Columbia, Aug. 23, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today an... Full story
Yahoo Finance • 2 years ago
InMed Announces Changes to its Board of Directors
VANCOUVER, British Columbia, Aug. 09, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleas... Full story
Yahoo Finance • 2 years ago
InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa
Phase 2 clinical trial recently expanded to include adolescents following independent review of early safety dataFirst adolescent patient with EB enrolled into clinical trial and completed treatment International patent granted for the use... Full story
Yahoo Finance • 2 years ago
InMed Announces Appointment of Chief Operating Officer
VANCOUVER, British Columbia, July 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today an... Full story
Yahoo Finance • 2 years ago
InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions
VANCOUVER, British Columbia, June 14, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today an... Full story
Yahoo Finance • 2 years ago
InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector
Produces highly pure d9-dominant THCV, a non-intoxicating cannabinoid Bolsters Company’s commercial portfolio, which also includes CBDV, CBC and CBTTHCV has been researched for a variety of potential benefits VANCOUVER, British Columbia,... Full story
Yahoo Finance • 2 years ago
InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
VANCOUVER, British Columbia, June 06, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today an... Full story
Yahoo Finance • 2 years ago
InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
VANCOUVER, British Columbia, June 02, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today an... Full story
Yahoo Finance • 3 years ago
InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update
Expands rare cannabinoid portfolio with the addition of CBT and CBDV Strengthens IP with publication of a patent application for novel cannabinoid analogsAdvances the pharmaceutical drug development programs in EB, glaucoma and neurodegene... Full story
Yahoo Finance • 3 years ago
InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert
Expands library of proprietary cannabinoid analogs for pharma R&DResearch collaboration initiated to screen analogs for therapeutic uses VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- InM... Full story
Yahoo Finance • 3 years ago
InMed to Participate in Upcoming Investor Conferences in April and May 2022
VANCOUVER, British Columbia, April 19, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, announc... Full story
